— Camrelizumab-rivoceranib extended PFS and OS compared to sorafenib
by Mike Bassett, Staff Writer, MedPage Today
July 28, 2023
The PD-1 inhibitor camrelizumab integrated with the VEGFR2-targeted inhibitor rivoceranib (likewise called apatinib) substantially enhanced survival compared to sorafenib (Nexavar) alone for the treatment of clients with unresectable hepatocellular cancer (HCC), a randomized stage III trial revealed.
At an average follow-up of 7.8 months, the average progression-free survival was 5.6 months with the 2 investigational representatives versus 3.7 months with sorafenib (HR 0.52, 95% CI 0.41-0.65, P< 0.0001), reported Shukui Qin, MD, of the Nanjing University of Chinese Medicine and Nanjing Medical University in China, and coworkers.
An interim analysis of general survival (OS) revealed that at a mean follow-up of 14.5 months, average OS was 22.1 months with camrelizumab-rivoceranib compared to 15.2 months with sorafenib (HR 0.62, 95% CI 0.49-0.80, P< 0.0001), they kept in mind in The Lancet.
The so-called CARES-310 research study “is the very first to report substantial progression-free survival and general survival advantages with the mix of an anti-PD-1 antibody and an orally administered, small-molecule, anti-angiogenic representative over sorafenib as first-line treatment for unresectable hepatocellular cancer,” Qin and associates composed.
The average OS in the mix group was the longest observed with any systemic treatment in stage III trials in unresectable HCC, they included, keeping in mind that the survival advantages were supported by a considerably greater reaction rate and more resilient reaction.
The unbiased action rate in the camrelizumab-rivoceranib group was 25% compared to 6% in the sorafenib group (P< 0.0001), while the mean period of action was 14.8 months versus 9.2 months, respectively, with a typical time to action of 1.9 months and 3.7 months.
In a commentary accompanying the research study, David J. Pinato, MD, PhD, of Hammersmith Hospital and Imperial College London, and associates, explained that the research study authors “have actually reached the essential turning point of providing the very first favorable stage III research study of an ICI-TKI [immune checkpoint inhibitor-tyrosine kinase inhibitor] mix in hepatocellular cancer.”
They